Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ABBOTT INDIA   MYLAN
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-23
MYLAN
Dec-18
ABBOTT INDIA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs22,4823,945-   
Low Rs16,1562,171-   
Sales per share (Unadj.) Rs2,517.01,815.3-  
Earnings per share (Unadj.) Rs446.849.3-  
Cash flow per share (Unadj.) Rs479.7389.2-  
Dividends per share (Unadj.) Rs325.000-  
Avg Dividend yield %1.70-  
Book value per share (Unadj.) Rs1,480.51,963.8-  
Shares outstanding (eoy) m21.25514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x7.71.7 455.6%   
Avg P/E ratio x43.262.0 69.7%  
P/CF ratio (eoy) x40.37.9 512.5%  
Price / Book Value ratio x13.01.6 837.9%  
Dividend payout %72.70-   
Avg Mkt Cap Rs m410,5131,573,481 26.1%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m5,6360-   
Avg. sales/employee Rs Th026,685.0-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0724.6-  
INCOME DATA
Net Sales Rs m53,487933,975 5.7%  
Other income Rs m1,5430-   
Total revenues Rs m55,030933,975 5.9%   
Gross profit Rs m12,055241,678 5.0%  
Depreciation Rs m700174,877 0.4%   
Interest Rs m16044,921 0.4%   
Profit before tax Rs m12,73821,880 58.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,244-3,481 -93.2%   
Profit after tax Rs m9,49425,361 37.4%  
Gross profit margin %22.525.9 87.1%  
Effective tax rate %25.5-15.9 -160.1%   
Net profit margin %17.82.7 653.7%  
BALANCE SHEET DATA
Current assets Rs m30,251521,531 5.8%   
Current liabilities Rs m12,060380,253 3.2%   
Net working cap to sales %34.015.1 224.8%  
Current ratio x2.51.4 182.9%  
Inventory Days Days8784 103.9%  
Debtors Days Days293 2.3%  
Net fixed assets Rs m15,135181,176 8.4%   
Share capital Rs m213497 42.7%   
"Free" reserves Rs m31,2480-   
Net worth Rs m31,4601,010,390 3.1%   
Long term debt Rs m01,090,535 0.0%   
Total assets Rs m45,3862,710,259 1.7%  
Interest coverage x80.71.5 5,424.3%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.20.3 342.0%   
Return on assets %21.32.6 820.3%  
Return on equity %30.22.5 1,202.3%  
Return on capital %41.03.2 1,289.4%  
Exports to sales %0.40-   
Imports to sales %10.80-   
Net fx Rs m-5,5080-   
CASH FLOW
From Operations Rs m8,934194,080 4.6%  
From Investments Rs m-1,477-100,318 1.5%  
From Financial Activity Rs m-6,387-90,414 7.1%  
Net Cashflow Rs m1,0701,608 66.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 82.88 Rs / USD

Compare ABBOTT INDIA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare ABBOTT INDIA With: ANG LIFESCIENCES INDIA  IOL CHEMICALS & PHARM.  DR. REDDYS LAB  WYETH  BANDARAM PHARMA PACKTECH  



Today's Market

Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3% Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3%(10:30 am)

Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.